Loxo Bayers Vitrakvi wins FDA approval. Now comes the hard part finding patients

Loxo, Bayer’s Vitrakvi wins FDA approval. Now comes the hard part: finding patients

An oncologist compared NTRK fusion patients to a needle in a haystack, but had some clues of how to find them. Still, drugs like Vitrakvi call for genomic sequencing of all cancer patients, he said.

More From BioPortfolio on "Loxo, Bayer’s Vitrakvi wins FDA approval. Now comes the hard part: finding patients"